Biotech Startups

TearSolutions develops Lacripep, a topical peptide therapy derived from the Lacritin protein for the treatment of dry eye disease, including cases associated with primary Sjögren's Syndrome. The company is running clinical trials of the drug candidate for patients with moderate to severe dry eye.

2 investors

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.

2 investors

Teitur Trophics is a biotech company developing therapies that target the sortilin family of receptors (SorCS-receptor biology) to activate the brain's natural survival pathways and preserve brain function. Its approach aims to address multiple neurodegenerative diseases by protecting brain cells from dying.

2 investors

Ten Lives makes sustainable cat snacks and food using fermentation to brew animal-free protein (microbes converting sugar to protein) that matches what cats eat in the wild. The products are vegan but formulated for carnivore health, aiming to reduce meat consumed by pets and the associated environmental impact.

2 investors

TendoNova develops microinvasive medical technology, including its Ocelot Nano device, to treat chronic tendon pain in patients. The company targets clinical use for patients with tendon injuries, including athletes.

2 investors

Tensor Bio develops a non-invasive, blood-based test that uses cell-free DNA methylation profiling and machine learning to stage liver fibrosis from a single blood draw. It targets MASH/MASLD diagnosis and monitoring, serving hepatologists, primary care clinicians, and biopharma partners who need to identify patients eligible for approved fibrosis therapies.

2 investors

Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases. The company is led by a team with expertise in biotech and precision medicine, targeting treatments for patients and caregivers affected by neurological conditions.

2 investors

Teora develops AI-driven, feed-based and foliar-spray biologics for farm health and growth, using bioinformatics and precision fermentation to prevent disease and boost yields without antibiotics, hormones, or cold-chain vaccines. Its SOLAQ platform is proven in aquaculture and aimed at scaling to livestock, poultry, companion animals, and agriculture.

2 investors

TerraVera develops technology and services supporting agricultural growers and beekeepers, with a focus on pollinator health and sustainable agriculture. The company positions its products around protecting ecosystems and improving outcomes for the farming and beekeeping community.

2 investors

Tesorai builds AI-powered data analysis software for life sciences researchers to extract insights from complex experimental datasets. The platform serves academic and biotech researchers who need to identify patterns and extract meaningful signals from massive datasets generated by high-throughput assays and other experiments.

2 investors

Tetra Therapeutics (Tetra Discovery Partners) was a discovery-based pharmaceutical company developing clinical programs including treatments for Fragile X Syndrome. It was acquired by Shionogi & Co. in 2020, and its former clinical trials and research programs are now managed by Shionogi Inc., a U.S. subsidiary.

2 investors

Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.

2 investors

Teva Pharmaceuticals is a global pharmaceutical company that discovers, develops, and manufactures medicines to treat chronic conditions for patients across 57 markets. The company operates through approximately 37,000 employees focused on improving health outcomes and delivering quality treatments worldwide.

2 investors

TG Therapeutics is a biopharmaceutical company focused on developing treatments for cancer patients. The company is committed to patient care and is guided by a board with extensive expertise in biotechnology, pharmaceutical development, financial management, and medical oncology.

2 investors

Electrospinning is a materials technology company that manufactures electrospun products, with a focus on sustainable operations and rigorous safety standards for both patients and workers. The company serves customers across medical and industrial applications.

2 investors

The Protein Brewery develops FERMOTEIN, a fermentation-based whole food ingredient made from fungal mycelium that provides complete protein and prebiotic fiber. The product targets the alternative protein and nutrition market as a plant-based, non-GMO food ingredient.

2 investors

The Good Face Project provides software for cosmetics and personal care R&D teams to formulate products, manage regulatory compliance, and assess ingredient safety and efficacy. Its cloud-based tools catalog ingredients, benchmark product formulas, and track global standards and regulations for beauty brands and formulators.

2 investors

Theraclion develops ultrasound-based medical devices for non-invasive treatment of vascular and thyroid conditions. The company designs robotic platforms combining ultrasound imaging and robotics for patients seeking alternatives to surgery.

2 investors

Developer of next-generation insulin solutions

2 investors

Theromics develops protein-based injectable nanogel accelerants (HeatSYNC and CryoSYNC) that improve energy transfer in soft tissue to make thermal ablation procedures larger, more spherical, and more effective, and to combine ablation with localized drug or immunotherapy delivery. It targets interventional oncology and conditions such as uterine fibroids, endometriosis, and breast cancer, and was spun out of Brown University.

2 investors

Therorna develops circular RNA-based therapeutic candidates and preventive medicines for diseases with unmet clinical needs. The company was founded in 2021 by domestic experts and overseas-educated PhDs to advance circular RNA technology in drug discovery and therapy.

2 investors

Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance. It is being developed for inflammatory bowel disease, including ulcerative colitis, and solid tumors.

2 investors

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.

2 investors

Third Pole develops portable and miniaturized devices that generate inhaled nitric oxide on-demand for hospital and mobile treatment of severe cardiopulmonary diseases and lung infections. The company uses a patented technology inspired by natural lightning to produce nitric oxide safely and efficiently from air and electricity.

2 investors